The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

Frontiers in Cardiovascular Medicine - Switzerland
doi 10.3389/fcvm.2018.00055
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Modelling Ponatinib Resistance in Tyrosine Kinase Inhibitor-Naïve and Dasatinib Resistant BCR-ABL1+ Cell Lines

Oncotarget
Oncology
2018English

BCR-ABL1 and Beyond

Pathology
Forensic MedicinePathology
2020English

BCR-ABL1-independent PI3Kinase Activation Causing Imatinib-Resistance

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2011English

Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib

BioResearch Open Access
BiochemistryGeneticsMolecular Biology
2015English

Eruptive Melanocytic Nevi Associated With Ponatinib

JAAD Case Reports
Dermatology
2018English

Ponatinib Suppresses the Development of Myeloid and Lymphoid Malignancies Associated With FGFR1 Abnormalities

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

Complete Molecular Response Induced by Nilotinib in a Patient Previously Treated With Imatinib, Nilotinib and Dasatinib

Clinical Management Issues
MedicineAccountingManagementBusiness
2015English

Nilotinib Treatment in Mouse Models of P190 BCR/Abl Lymphoblastic Leukemia

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2007English

Rechallenge of Ponatinib in Chronic Myeloid Leukaemia After Hepatotoxicity

Hong Kong Medical Journal
Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy